Real-world evaluation of JBA Glucotrojan® supplementation in regulating postprandial glycemic response in healthy adults
Keywords:
GlucoTrojan, Blood glucose, Postprandial glucose response, Glycemic indexAbstract
Background and aim: Our modern diet, abundant in carbohydrates and sugars, often causes surges in blood glucose levels that facilitate the development of diabetes and obesity. This public health crisis has propelled the innovation of GlucoTrojan®, a blend of white mulberry leaf, mango leaf, and banana stem juice extracts. Our study aims to examine the effects of GlucoTrojan® on the postprandial blood glucose response after consuming white rice.
Methods: We conducted a real-world, prospective interventional study (clinicaltrials.gov registration: NCT06509204) to examine the effects of consuming cooked white rice (82 g of net carbohydrates) with and without GlucoTrojan® on postprandial blood glucose levels among healthy individuals. A continuous glucose monitoring (CGM) device was used to measure blood glucose levels. Tastermonial mobile application was used to collect data on food and drink consumption. The incremental area under the curve (iAUC) measuring glycemic index and postprandial glucose spikes were calculated to assess the effects of GlucoTrojan®.
Results: Of the 50 individuals who participated, 25 (mean age of 40.3 years; 36% females) provided complete and valid data for analyses. Consuming white rice with GlucoTrojan® significantly reduced the mean postprandial blood glucose levels by 14 ± 6 mg/dl (P < .0001) over 2 hours compared to white rice consumption alone, corresponding to a 26.1% reduction. GlucoTrojan® also significantly lowered the glycemic index of white rice by a mean of 1166 ± 610 mg/dL × min, equivalent to a 33% reduction compared to no GlucoTrojan® (P < .0001).
Conclusions: The findings indicate that GlucoTrojan® significantly modulates postprandial glucose responses, lowering blood glucose levels and glycemic index. Overall, our study supports GlucoTrojan® as a promising supplement for managing blood glucose levels.
References
1. Zimmet PZ. Diabetes and its drivers: the largest epidemic in human history? Clin Diabetes Endocrinol. 2017;3:1. doi: 10.1186/s40842‑016‑0039‑3
2. The Centers for Disease Control and Prevention. Adult obesity facts 2022. [Available from: https://www.cdc.gov/obesity/data/adult.html]
3. The Centers for Disease Control and Prevention. By the numbers: diabetes in America 2022. [Available from: https://www.cdc.gov/diabetes/health‑equity/diabetes‑by‑the‑numbers.html]
4. Hostalek U. Global epidemiology of prediabetes – present and future perspectives. Clin Diabetes Endocrinol. 2019;5:5. doi: 10.1186/s40842‑019‑0080‑0
5. Temelkova‑Kurktschiev T, Stefanov T. Lifestyle and genetics in obesity and type 2 diabetes. Exp Clin Endocrinol Diabetes. 2012;120:1‑6. doi: 10.1055/s‑0031‑1285832
6. DiNicolantonio JJ, Berger A. Added sugars drive nutrient and energy deficit in obesity: a new paradigm. Open Heart. 2016;3:e000469. doi: 10.1136/openhrt‑2016‑000469
7. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840‑6. doi: 10.1038/nature05482
8. Ramappa VK, Srivastava D, Singh P, et al. Mulberry 1‑deoxynojirimycin (DNJ): an exemplary compound for therapeutics. J Hortic Sci Biotechnol. 2020;95:679‑86. doi: 10.1080/14620316.2020.1760738
9. Li YG, Ji DF, Zhong S, et al. 1‑deoxynojirimycin inhibits glucose absorption and accelerates glucose metabolism in streptozotocin‑induced diabetic mice. Sci Rep. 2013;3:1377. doi: 10.1038/srep01377
10. Asai A, Nakagawa K, Higuchi O, et al. Effect of mulberry leaf extract with enriched 1‑deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism. J Diabetes Investig. 2011;2:318‑23. doi: 10.1111/j.2040‑1124.2011.00101.x
11. Lown M, Fuller R, Lightowler H, et al. Mulberry‑extract improves glucose tolerance and decreases insulin concentrations in normoglycaemic adults: results of a randomised double‑blind placebo‑controlled study. PLoS One. 2017;12:e0172239. doi: 10.1371/journal.pone.0172239
12. Riche DM, Riche KD, East HE, Barrett EK, May WL. Impact of mulberry leaf extract on type 2 diabetes (Mul‑DM): a randomized, placebo‑controlled pilot study. Complement Ther Med. 2017;32:105‑8. doi: 10.1016/j.ctim.2017.04.006
13. Wang R, Li Y, Mu W, et al. Mulberry leaf extract reduces the glycemic indexes of four common dietary carbohydrates. Medicine (Baltimore). 2018;97:e11996. doi: 10.1097/MD.0000000000011996
14. Thaipitakwong T, Supasyndh O, Rasmi Y, Aramwit P. A randomized controlled study of dose‑finding, efficacy, and safety of mulberry leaves on glycemic profiles in obese persons with borderline diabetes. Complement Ther Med. 2020;49:102292. doi: 10.1016/j.ctim.2019.102292
15. Thondre PS, Lightowler H, Ahlstrom L, et al. Mulberry leaf extract improves glycaemic response and insulaemic response to sucrose in healthy subjects: results of a randomized, double blind, placebo‑controlled study. Nutr Metab (Lond). 2021;18:41. doi: 10.1186/s12986‑021‑00571‑2
16. Gheldof N, Francey C, Rytz A, et al. Effect of different nutritional supplements on glucose response of complete meals in two crossover studies. Nutrients. 2022;14. doi: 10.3390/nu14132674
17. Mudra M, Ercan‑Fang N, Zhong L, Furne J, Levitt M. Influence of mulberry leaf extract on the blood glucose and breath hydrogen response to ingestion of 75 g sucrose by type 2 diabetic and control subjects. Diabetes Care. 2007;30:1272‑4. doi: 10.2337/dc06‑2120
18. McCarthy CM. Randomized controlled trials. Plast Reconstr Surg. 2011;127:1707‑12. doi: 10.1097/PRS.0b013e31820da3eb
19. Brouns F, Bjorck I, Frayn KN, et al. Glycaemic index methodology. Nutr Res Rev. 2005;18:145‑71. doi: 10.1079/NRR2005100
20. Crangle C, Piccin B, Hyde L, Östman E. Retrospective analysis of postprandial glucose‑response data collected in a free‑living environment. J Intell Med Healthc. 2022;1:91‑102. doi: 10.32604/jimh.2022.038379
21. Jansen LT, Yang N, Wong JMW, et al. Prolonged glycemic adaptation following transition from a low‑ to high‑carbohydrate diet: a randomized controlled feeding trial. Diabetes Care. 2022;45:576‑84. doi: 10.2337/dc21‑1970
22. Chen S, Xi M, Gao F, et al. Evaluation of mulberry leaves’ hypoglycemic properties and hypoglycemic mechanisms. Front Pharmacol. 2023;14:1045309. doi: 10.3389/fphar.2023.1045309
23. Iwagami M, Takeuchi Y. Introduction to self‑controlled study design. Ann Clin Epidemiol. 2021;3:67‑73. doi: 10.37737/ace.3.3_67
24. Muthayya S, Sugimoto JD, Montgomery S, Maberly GF. An overview of global rice production, supply, trade, and consumption. Ann NY Acad Sci. 2014;1324:7‑14. doi: 10.1111/nyas.12540
25. Mantantzis K, Schlaghecken F, Sunram‑Lea SI, Maylor EA. Sugar rush or sugar crash? A meta‑analysis of carbohydrate effects on mood. Neurosci Biobehav Rev. 2019;101:45‑67. doi: 10.1016/j.neubiorev.2019.03.016
26. Aller EE, Abete I, Astrup A, Martinez JA, van Baak MA. Starches, sugars and obesity. Nutrients. 2011;3:341‑69. doi: 10.3390/nu3030341
27. Vlachos D, Malisova S, Lindberg FA, Karaniki G. Glycemic index (GI) or glycemic load (GL) and dietary interventions for optimizing postprandial hyperglycemia in patients with T2 diabetes: a review. Nutrients. 2020;12. doi: 10.3390/nu12061561
28. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597‑605. doi: 10.1161/CIRCULATIONAHA.106.621854
29. Prasad C, Davis KE, Imrhan V, Juma S, Vijayagopal P. Advanced glycation end products and risks for chronic diseases: intervening through lifestyle modification. Am J Lifestyle Med. 2019;13:384‑404. doi: 10.1177/1559827617708991
30. Kumar M, Saurabh V, Tomar M, et al. Mango (Mangifera indica L.) leaves: nutritional composition, phytochemical profile, and health‑promoting bioactivities. Antioxidants (Basel). 2021;10. doi: 10.3390/antiox10020299
31. Zivkovic J, Kumar KA, Rushendran R, et al. Pharmacological properties of mangiferin: bioavailability, mechanisms of action and clinical perspectives. Naunyn Schmiedebergs Arch Pharmacol. 2023. doi: 10.1007/s00210‑023‑02682‑4
32. Kulkarni VM, Rathod VK. Exploring the potential of Mangifera indica leaves extract versus mangiferin for therapeutic application. Agric Nat Resour. 2018;52:155‑61. doi: 10.1016/j.anres.2018.07.001
33. Panigrahi PN, Dey S, Sahoo M, Dan A. Antiurolithiatic and antioxidant efficacy of Musa paradisiaca pseudostem on ethylene glycol‑induced nephrolithiasis in rat. Indian J Pharmacol. 2017;49:77‑83. doi: 10.4103/0253‑7613.201026
34. Abu Zarin M, Tan JS, Murugan P, Ahmad R. Investigation of potential anti‑urolithiatic activity from different types of Musa pseudo‑stem extracts in inhibition of calcium oxalate crystallization. BMC Complement Med Ther. 2020;20:317. doi: 10.1186/s12906‑020‑03113‑0
35. Dikshit P, Shukla K, Tyagi MK, et al. Antidiabetic and antihyperlipidemic effects of the stem of Musa sapientum Linn. in streptozotocin‑induced diabetic rats. J Diabetes. 2012;4:378‑85. doi: 10.1111/j.1753‑0407.2012.00198.x
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Guillermo Daniel Repizo, Le Quang Huan, Shin Jie Yong, Bude Sethaputra-Piccin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
